Physician profile
Rangram Chandran
NPI 1194714642
$2,084.73
in general payments reported to CMS, 2019-2025
13 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $98.67 · 2021: $160 · 2022: $195 · 2023: $367 · 2024: $468 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $492.86 | 2019-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $262.31 | 2019 | |
| Apellis Pharmaceuticals, INC. | $230.66 | 2024-2025 | Syfovre |
| Astellas Pharma US INC | $226.84 | 2023-2025 | Izervay |
| Biogen, INC. | $200.46 | 2022-2024 | Byooviz |
| Mallinckrodt Hospital Products INC. | $160.30 | 2020-2023 | Acthar |
| Dutch Ophthalmic, USA | $138.74 | 2025 | Eva, Combined Machine, Tissueblue |
| Carl Zeiss Meditec USA, INC. | $89.96 | 2023-2024 | Lumera 700, Cirrus Hd-Oct |
| Carl Zeiss Meditec, INC. | $85.70 | 2019 | |
| Genentech USA, INC. | $84.89 | 2022-2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $57.04 | 2025 | Purified Cortrophin Gel, Iluvien |
| Regeneron Healthcare Solutions, INC. | $35.57 | 2019-2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rangram Chandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.